As first reported by Med-Tech Insights, Optibrium, a UK-based leader in AI and software solutions for molecular design, has announced a strategic multi-million-pound financing deal with Shawbrook Bank. This partnership aims to accelerate Optibrium’s expansion and enhance its core technologies, including generative chemistry, collaborative design, and 3D molecular modelling tools. The funding will support the company’s mission to speed up pharmaceutical research for global biotech and pharma teams.
Source: optibrium.com.
The new financing package, structured around Optibrium’s Annual Recurring Revenue (ARR), provides both immediate capital for ongoing initiatives and committed facilities for future development. It builds on sustained investment from private equity firm Kester Capital, which has backed Optibrium since 2021. During this time, the company has seen rapid adoption of its AI-powered platforms, which help researchers tackle complex challenges in drug discovery more effectively.
The deal comes amid a surge in demand for computer-aided drug discovery (CADD) tools, with the market projected to grow from USD 4.21 billion in 2024 to USD 13.08 billion by 2034. Optibrium’s platforms are already in use by over 160 organizations worldwide, underscoring their value in enabling more informed decisions early in the R&D pipeline. The company, founded in 2009 and operating in both the UK and US, combines scientific rigor with computational innovation to support data-driven molecular design.
Statements from key stakeholders—Kester Capital’s Peter Ralph, Optibrium CFO Ally Henderson, and Shawbrook Director Jack Longden—all highlight the alignment between the financing package and Optibrium’s long-term strategic goals. Each emphasized the importance of flexible capital in supporting sustained innovation, global reach, and delivering meaningful outcomes for drug discovery teams worldwide.
With this latest financing boost, Optibrium is well-positioned to expand its technological edge and global footprint. The deal not only validates the company’s momentum and impact in the AI-powered drug discovery space, but also reinforces investor confidence in the transformative role of CADD solutions for the future of pharmaceutical research.
